脂质体多柔比星治疗淋巴瘤的疗效

目的：探讨脂质体多柔比星用于临床治疗淋巴瘤的疗效以及安全性。方法：选取90例淋巴瘤患者作为研究对象，均采用脂质体多柔比星治疗，对患者临床资料、治疗结果、随访情况等进行回顾性分析。结果：90例淋巴瘤患者治疗总有效率为74.44%，初治者总有效率（79.25%）与复治者（67.57%）相近，组间无明显差异（P >0.05）。常见不良反应为骨髓抑制、心电图异常、心功能异常等；患者随访3年生存率为62.22%，初治者（71.70%）略高于复治者（48.65%），但组间比较差异无显著性（P >0.05）。结论：采用脂质体多柔比星临床治疗淋巴癌，效果显著，不良反应较小，安全性高，建议在临床可作为治疗淋巴瘤的首选药物进行推广应用。

Clinical effcet of liposome doxorubicin in the treatment on lymphoma

Objective:To explore the efficacy and safety of liposome doxorubicin to treat the lymphoma. Methods:Ninety patients with lymphoma were selected as subjects,liposome doxorubicin was applied for patients. Results:The total effective rate of 90 patients with lymphoma was 74. 44% ,the total effective rate of initial treatment(79. 25% ) was similar to that of re - treatment(67. 57% ),no significant differences were found between groups(P > 0. 05). Common adverse reactions involved bone marrow suppression,abnormal electrocardiogram(ECG),abnormal cardiac function. The survival rate of patients after 3 years of follow - up was 62. 22% ,and survival rate of patients undergoing initial treatment(71. 70% )was slightly higher than patients undergoing re - treatment(48. 65% ),while the differ-ence was not significant(P > 0. 05). Conclusion:The liposome doxorubicin for lymphoma has obvious efficacy with less adverse reaction and high safety.